蔗糖铁注射液治疗急性上消化道出血后缺铁性贫血的观察

Observation of Iron Sucrose Injection in Treatment of Iron Deficiency Anemia after Acute Upper Gastrointestinal Hemorrhage

目的探讨蔗糖铁注射液治疗急性上消化道出血后缺铁性贫血的临床效果及安全性。方法选取急性非静脉曲张性上消化道出血所致缺铁性贫血82例患者,按随机数字表法分为对照组和观察组,各41例。2组患者均常规应用质子泵抑制剂及补液扩容治疗,观察组给予静脉注射蔗糖铁注射液治疗,对照组口服琥珀酸亚铁片治疗,观察2组患者治疗4周末临床效果;比较2组患者治疗2、4周后的血红蛋白(Hb)指标变化情况;观察2组患者治疗药物的不良反应。结果治疗4周末,观察组总有效率为95.1%,高于对照组的78.0%,差异有统计学意义(P<0.05)。治疗2、4周后,观察组Hb上升水平高于对照组,差异有统计学意义(P<0.01)。治疗过程中,2组患者均无严重不良反应发生。结论静脉注射蔗糖铁注射液治疗急性上消化道出血后缺铁性贫血效果较好,无明显不良反应。

Objective To investigate the clinical efficacy and safety of iron sucrose injection in the treatment of iron deficiency anemia after acute upper gastrointestinal hemorrhage.Methods 82 patients with iron deficiency anemia caused by acute non-varicose upper gastrointestinal hemorrhage were selected and divided into the control group and the observation group by the random number table method,with 41 cases in each group.The two groups were both treated with routine proton pump inhibitor and fluid supplementation and volume expansion.The observation group was treated with intravenous iron sucrose injection,while the control group with ferrous succinate tablets.The clinical effects in the two groups were observed at the end of 4 weeks,the changes of hemoglobin(Hb)indexes between the two groups were compared after 2 and 4 weeks of the treatment,and the adverse reactions to therapeutic drugs in the two groups were observed.Results At the end of 4 weeks,the total effective rate in the observation group(95.1%)was higher than that(78.0%)in the control group,and the difference was statistically significant(P<0.05).After 2 and 4 weeks of the treatment,the Hb level in the observation group was higher than that in the control group,with statistically significant differences(P<0.01).During the treatment,no serious adverse reactions occurred in both groups.Conclusion The effect of intravenous iron sucrose injection on the treatment of iron deficiency anemia after acute upper gastrointestinal hemorrhage was much better,without obvious adverse reactions.